BOLT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system...

Stats
Today's Volume	154 818
Average Volume	130 266
Market Cap	45.76M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.510 ) 2024-05-09
Last Dividend	$0.0900 ( 2014-08-29 )
Next Dividend	$0 ( N/A )
P/E	-0.660
ATR14	$0.00800 (0.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Yonehiro Grant	Buy	235 000	Stock Option (Right to Buy)
2024-03-04	Perez Edith A.	Buy	235 000	Stock Option (Right to Buy)
2024-03-04	Schatzman Randall C	Buy	654 000	Stock Option (Right to Buy)
2024-03-04	Quinn William P.	Buy	235 000	Stock Option (Right to Buy)
2023-12-31	Yonehiro Grant	Buy	0

INSIDER POWER
72.53
Last 93 transactions
Buy: 5 349 325 \| Sell: 1 125 168

Bolt Biotherapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations
SITM	-0.817
IRBT	-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bolt Biotherapeutics, Financials

Annual	2023
Revenue:	$7.88M
Gross Profit:	$5.99M (76.08 %)
EPS:	$-1.830

Q4	2023
Revenue:	$2.09M
Gross Profit:	$1.59M (76.21 %)
EPS:	$-0.470

Q3	2023
Revenue:	$2.53M
Gross Profit:	$2.07M (81.72 %)
EPS:	$-0.430

Q2	2023
Revenue:	$1.43M
Gross Profit:	$244 000 (17.03 %)
EPS:	$-0.480

Financial Reports:

No articles found.

Bolt Biotherapeutics, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bolt Biotherapeutics, Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0.326 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0500	2012-03-06
Last Dividend	$0.0900	2014-08-29
Next Dividend	$0	N/A
Payout Date	2014-10-02
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$0.830	--
Avg. Dividend % Per Year	0.00%	--
Score	1.61	--
Div. Sustainability Score	0.326
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-18)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

1.61

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-8.60	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.424	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.501	1.500	-6.68	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	5.16	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.06	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.528	1.500	8.18	10.00	[0.2 - 2]
debtRatioTTM	0.127	-1.500	7.89	-10.00	[0 - 0.6]
interestCoverageTTM	53.10	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.832	2.00	-0.611	-1.222	[0 - 30]
freeCashFlowPerShareTTM	-1.838	2.00	-0.919	-1.838	[0 - 20]
debtEquityRatioTTM	0.179	-1.500	9.28	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.577	1.000	3.72	3.72	[0.2 - 0.8]
operatingProfitMarginTTM	-9.67	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-3.44	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0493	0.800	-3.00	-2.40	[0.5 - 2]
Total Score				0.326

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.672	1.000	-0.169	0	[1 - 100]
returnOnEquityTTM	-0.501	2.50	-4.29	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.838	2.00	-0.613	-1.838	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.832	2.00	-0.611	-1.222	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00501	1.500	-3.30	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-8.83	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.76

Bolt Biotherapeutics,

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.